- AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting
- AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting
- Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA
Key statistics
On Tuesday, Ascentage Pharma Group International (6855:HKG) closed at 16.80, 8.95% above its 52-week low of 15.42, set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.58 |
---|---|
High | 17.40 |
Low | 16.50 |
Bid | 16.78 |
Offer | 16.80 |
Previous close | 16.58 |
Average volume | 933.51k |
---|---|
Shares outstanding | 290.21m |
Free float | 212.89m |
P/E (TTM) | -- |
Market cap | 4.81bn HKD |
EPS (TTM) | -3.54 HKD |
Data delayed at least 15 minutes, as of Apr 23 2024 09:09 BST.
More ▼